aibioNovo Nordisk
Top story · Sep 14, 2026 · aibio.space
Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback
All TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations.
- Ticker
- NOVO B
- Listing
- OMXCOP, Denmark
- Next date
- Q4 2026
- Chief executive
- Mike Doustdar
Desk view · Opinion · Updated Oct 22, 2026
Novo has the cash and the pill; it needs new products to stop the U.S. slide
Novo still earns large profits from semaglutide, and the Wegovy pill is selling well. But U.S. sales are falling, its non-GLP-1 bets have disappointed, and the company now depends on Q4 approvals and licensed assets to change its direction.
Read the full desk viewaibio.space Investor Rank · Opinion
7/10 Positive view
Semaglutide still earns large profits and cash flow, with filed drugs facing Q4 decisions, but U.S. sales are falling and non-GLP-1 bets have disappointed.
- Technology
- 2/2
- Odds
- 2/2
- Balance sheet
- 2/2
- Risk
- 1/2
- Momentum
- 0/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven but aging. Semaglutide brands sold more than DKK 50 billion in Q2, and the Wegovy pill adds an oral version.
- Odds
- Good for filed drugs. CagriSema and the 25 mg pill face U.S. decisions in Q4 2026; filed drugs are approved about 90.6% of the time.
- Balance sheet
- Strong cash generation. H1 free cash flow was DKK 55.3 billion, funding a buyback of up to DKK 15 billion.
- Main risk
- Losing U.S. share. U.S. sales fell 2% at constant exchange rates in Q2 as Lilly grew 48%.
- Watch next
- Fourth-quarter FDA decisions. CagriSema and oral semaglutide 25 mg are due before year end.
Top news on Novo
- Financings
Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback
All TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations.
Questions investors ask
What is aibio.space's Investor Rank for Novo Nordisk?
7 out of 10, our positive view. Semaglutide still earns large profits and cash flow, with filed drugs facing Q4 decisions, but U.S. sales are falling and non-GLP-1 bets have disappointed. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What is Novo Nordisk's 2026 sales outlook?
Novo expects 2026 adjusted sales and adjusted operating profit to range from flat to down 6% at constant exchange rates. It raised that range on August 4 from declines of 4% to 12%. Source
How much did the Wegovy pill sell in Q2 2026?
The Wegovy pill booked DKK 3.2 billion in second-quarter 2026 sales. Weekly U.S. prescriptions passed 265,000 in the week ending July 17. Source
Why did Novo Nordisk's ZEUS trial fail?
Ziltivekimab lowered the inflammation markers IL-6 and hsCRP but did not reduce heart attacks, strokes or cardiovascular deaths (hazard ratio 0.99). Serious infections were more common on the drug. Source
When will the FDA decide on CagriSema?
Novo's second-quarter 2026 report lists a U.S. decision on CagriSema in the fourth quarter of 2026. Source
What did Novo Nordisk pay Hengrui for HRS-1596?
Novo agreed to pay $300 million upfront, with total potential value up to $2.6 billion including milestones, plus royalties. The deal is expected to close in the fourth quarter of 2026. Source
Is Novo Nordisk a smaller reporting company?
SEC records list Novo Nordisk A/S's filer category as: Large accelerated filer. Source
Where is Novo Nordisk headquartered?
SEC records list its business address as NOVO ALLE DK 2880, BAGSVAERD DENMARK, Denmark, 00000. Source
When does Novo Nordisk's fiscal year end?
Novo Nordisk A/S's fiscal year ends on December 31, per SEC records. Source
What did Novo Nordisk last file with the SEC?
Its most recent filing in our record is a 6-K filed 2026-10-19. All of its filings are on SEC EDGAR. Source
What industry is Novo Nordisk in?
Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source
Which other companies' news mentions Novo Nordisk?
Novo Nordisk is named in 1 of our story about other companies, most recently: "Ascendis takes back obesity rights from Novo Nordisk and authorizes $400 million buyback" (Sep 14, 2026). Source
How can I follow Novo Nordisk (NOVO B) news?
Press Follow on this page to add Novo Nordisk to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Novo Nordisk so far, in Financings. Source
Legal and investor matters
- Litigation
Novo Nordisk faces putative class actions over June 2026 IT security incident
Novo Nordisk's interim report for the first half of 2026 says the company is a defendant in multiple putative class action lawsuits in the United States related to an IT security incident announced by press release on 2026-06-11. The complaints assert negligence and other claims on behalf of individuals who allege their personal and protected health information was compromised. The report names no court or case number.
- Other
Novo Nordisk raises 2026 adjusted sales and operating profit outlook
On 2026-08-04 Novo Nordisk said second-quarter 2026 adjusted sales rose 7% at constant exchange rates and adjusted operating profit rose 11%. The company raised its full-year 2026 adjusted sales and adjusted operating profit outlook at constant exchange rates. The adjusted growth rates exclude the non-recurring impact of provision reversals related to the 340B Drug Pricing Program in the US, and adjusted operating profit also excludes DKK 6.3 billion of non-cash impairment charges.
- Litigation
U.S. Supreme Court denies Novo Nordisk petition in Inflation Reduction Act suit
On 2026-05-18 the U.S. Supreme Court denied Novo Nordisk's petition for certiorari seeking review of the Third Circuit's decision affirming dismissal of its lawsuit challenging the pricing provisions of the Inflation Reduction Act. The interim report for the first half of 2026 says no further appeals can be taken and the matter is closed.
- Class action
Amended complaint filed in ADR securities class action; CEO dropped as defendant
On 2026-04-03 an amended complaint was filed in the securities class action in the District of New Jersey brought by a proposed class of purchasers of Novo Nordisk ADRs between 2024-11-06 and 2025-07-28. Novo Nordisk describes it as containing similar allegations to the 2025-08-01 original complaint, namely that the company misled investors about its potential to capitalise on the compounded market for GLP-1 medicines. Current CEO Maziar Mike Doustdar, a defendant in the original complaint, is not named in the amended one. Novo Nordisk does not expect a material impact.
- Class action
Catalent securities class action settled for amount covered by Catalent insurance
Novo Nordisk's Annual Report 2025 says a securities class action filed in February 2023 in the District of New Jersey by City of Warwick Retirement System against Catalent and others settled in November 2025 for an amount fully covered through Catalent insurance policies. Novo Nordisk acquired three Catalent sites in December 2024, including a portion of any potential liability. Final court approval was anticipated in mid-2026.
- Litigation
Jury returns defense verdict for Novo Nordisk in NovoSeven qui tam case
A 2015 qui tam suit by a former employee alleged kickbacks and false claims relating to NovoSeven. After the Department of Justice declined to intervene, the relator and the Washington State Attorney General proceeded, and a jury returned a defense verdict for Novo Nordisk in November 2025. The Annual Report 2025 says they have appealed to the Ninth Circuit and that Novo Nordisk does not expect a material impact.
- Regulatory
340B ruling final: Novo Nordisk to recognise USD 4.2 billion of 340B provisions as revenue
HRSA dismissed a 340B administrative dispute resolution petition against Novo Nordisk on 2025-12-04, and the decision became final on 2026-01-20 after a reconsideration deadline expired. Novo Nordisk said the legal uncertainty was resolved only after the 2025 balance sheet date and that it would recognise USD 4.2 billion of revenue, the entire amount of its 340B statutory discount provisions, in the first quarter of 2026. On 2026-02-03 it said its 2026 outlook would be positively impacted by a reversal of USD 4.2 billion of sales rebate provisions related to the 340B program.
- Governance
Novo Nordisk shareholders elect new chair and board members at extraordinary meeting
At an extraordinary general meeting on 2025-11-14, Lars Rebien Sørensen was elected chair, Cees de Jong vice chair, and Britt Meelby Jensen and Stephan Engels members of the board. Chair Helge Lund, vice chair Henrik Poulsen and five other directors stepped down. The board had called the meeting on 2025-10-21 after it could not reach a common understanding with the Novo Nordisk Foundation, which controls the majority of votes, on board composition.
- Other
Novo Nordisk confirms unsolicited proposal to acquire Metsera
On 2025-10-30 Novo Nordisk confirmed it had submitted an unsolicited proposal to acquire Metsera, Inc. at 56.50 USD per share in cash, an approximate equity value of 6.5 billion USD, plus contingent value rights of up to 21.25 USD per share tied to clinical and regulatory milestones. The announcement does not say whether Metsera accepted the proposal.
- Other
Novo Nordisk agrees to acquire Akero Therapeutics for 54 USD per share plus CVR
On 2025-10-09 Novo Nordisk announced a definitive agreement to acquire Akero Therapeutics, which is developing the FGF21 analogue efruxifermin for MASH. The price is 54 USD per share in cash at closing, about 4.7 billion USD, plus a contingent value right of 6 USD per share, about 0.5 billion USD. The Q3 2025 report said the Akero deal was included in cash flow guidance, contingent on closing timing.
- Other
Novo Nordisk plans to cut about 9,000 roles with DKK 8 billion restructuring cost
On 2025-09-10 Novo Nordisk announced a company-wide transformation under which it intends to reduce its global workforce by approximately 9,000 of 78,400 positions, with around 5,000 in Denmark. It expects DKK 8 billion of annualised savings by the end of 2026 and one-off restructuring costs of DKK 8 billion. It updated its 2025 operating profit growth outlook to 4 to 10 percent at constant exchange rates.
- Class action
Securities class action filed over GLP-1 compounding disclosures
On 2025-08-01 a class action was filed in the District of New Jersey against Novo Nordisk, former CEO Lars Fruergaard Jørgensen, CEO Maziar Mike Doustdar, CFO Karsten Munk Knudsen and executive Dave Moore, for purchasers of Novo Nordisk ADRs between 2025-05-07 and 2025-07-28. The complaint alleges the company misled investors about the compounded GLP-1 market. Novo Nordisk does not expect a material impact.
- Governance
Novo Nordisk lowers 2025 outlook and names Doustdar CEO
On 2025-07-29 Novo Nordisk lowered its 2025 outlook to sales growth of 8 to 14 percent and operating profit growth of 10 to 16 percent at constant exchange rates. The same day it named Maziar Mike Doustdar president and chief executive officer, effective 2025-08-07, succeeding Lars Fruergaard Jørgensen. A securities class action filed 2025-08-01 covers purchases of Novo Nordisk ADRs from 2025-05-07 to 2025-07-28.
- Governance
Novo Nordisk announces CEO Jørgensen will step down
On 2025-05-16 Novo Nordisk announced that Lars Fruergaard Jørgensen would step down as CEO by mutual agreement with the board, and Lars Rebien Sørensen, chair of the Novo Nordisk Foundation, would join the board as an observer. The company said the changes were made in light of recent market challenges and the share price since mid-2024, and that the Foundation had expressed a wish to increase its board representation.
- Class action
Securities class action filed over REDEFINE-1 trial disclosures
On 2025-01-24 a class action was filed in the District of New Jersey against Novo Nordisk, former CEO Lars Fruergaard Jørgensen and R&D chief Martin Holst Lange for purchasers of Novo Nordisk ADRs between 2022-11-02 and 2024-12-19. The Annual Report 2025 says the suit relates to REDEFINE-1 and alleges the company failed to disclose the nature of the dosages given to study patients. Novo Nordisk does not expect a material impact.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Semaglutide (Ozempic, Wegovy, Wegovy pill) | Type 2 diabetes, obesity, MASH | Marketed Source |
| CagriSema | Obesity | Under FDA review; U.S. decision listed for Q4 2026 Source |
| Oral semaglutide 25 mg (Ozempic pill) | Type 2 diabetes | Under FDA review; decision expected Q4 2026 Source |
| Denecimig | Hemophilia A | FDA review extended; positive CHMP opinion Sept 2026 Source |
| Ziltivekimab | Heart failure (HERMES), acute heart attack (ARTEMIS) | Phase 3; ZEUS failed July 2026 Source |
| HRS-1596 (licensed from Hengrui) | Obesity, type 2 diabetes | Phase 1-ready; deal closing expected Q4 2026 Source |
Opinion · Devil's advocate
Fact-check-o-meter
Novo's '9 in 10' liver claim rests on 23 of 26 patients, and its 'raised outlook' still points to flat or lower sales
Novo's Q2 report and its later announcements are internally consistent, and the company states the bad news on ziltivekimab and denecimig plainly. The gaps are in framing: the headline leads with adjusted profit and a raised outlook that still points to flat or lower sales, and the liver-fat release headlines a post hoc figure from 26 patients. The Q2 report's legal section lists IT-incident class actions and patent suits, not securities suits.
Science · weight high
'9 in 10' liver fat result is 23 of 26 patients in a post hoc analysis
The company said: "9 in 10 achieved normal liver fat levels: Among participants with liver fat above 5%, 88.5% in the pooled group of people taking Wegovy® (injectable semaglutide 7.2 and 2.4 mg) achieved normal liver fat levels below 5% by week 72" source
The record says: The same release says it presents "post hoc analysis of data from a STEP UP trial sub-population with 55 participants", that "26 participants entered the trials with liver fat above 5% and 88.5% of them" reached the below-5% threshold, which the release counts as 23 participants, and that the analysis "was not a pre-specified primary or secondary endpoint of the parent trials". It also says "Semaglutide 7.2 mg is not being investigated for the treatment of MASH." source
Our view: The headline is arithmetically right and the small numbers are in the release. But 23 patients in an exploratory subgroup, with no stated comparison to placebo for this figure, is thin support for a headline about 9 in 10 adults. It also shows an effect on a liver fat measure, not on MASH outcomes.
Press release vs filing · weight medium
'Raises outlook' headline leads with adjusted figures
The company said: "Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook" source
The record says: The same report says "Q2 2026 reported operating profit decreased by 16% at CER, with growth negatively impacted by the US 340B rebate provision reversal in Q2 2025 as well as non-cash impairment charges of DKK 6.3 billion in Q2 2026 related to intangible pipeline assets, including monlunabant (DKK 4.0 billion)." The raised outlook reads: "Adjusted sales growth for 2026 is now expected to be 0% to -6% at CER and adjusted operating profit growth is now expected to be 0% to -6% at CER." source
Our view: The adjustments are defined and reconciled in the report, so this is a framing point, not a contradiction. Reading only the headline, one would miss that reported operating profit fell and that even the raised guidance is a range of flat to down 6%.
Press release vs filing · weight medium
Denecimig delay: the facility remediation news came after the Q2 report
The company said: "Denecimig US & EU decision" source
The record says: The October 2 announcement says the FDA "has informed Novo that the ongoing facility remediation activities are the cause for extension of the Agency's review" and that Novo had anticipated "a regulatory decision in the third quarter of 2026". It adds that "the FDA performed a pre-license inspection of the manufacturing site and provided feedback" after the September 2025 submission, without giving the date of that feedback. source
Our view: The Q2 report's milestone table lists a denecimig decision for 2026 and does not mention facility remediation. The filing does not say when Novo learned of the FDA's feedback, so we cannot say the Q2 report was out of date. The announcement is clear that the FDA found no efficacy or safety deficiencies.
Science · weight low
ZEUS was a clean negative, with an impairment still to come
The company said: "this did not translate into major adverse cardiovascular events (MACE) risk reduction versus placebo in people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88 to 1.11)" source
The record says: ClinicalTrials.gov lists ZEUS (NCT05021835) as randomized, quadruple-masked, with 6,385 actual participants and time to first 3-point MACE as the primary outcome. The announcement says ZEUS "will not impact Novo Nordisk's previously communicated adjusted operating profit outlook for 2026 but will result in a non-cash impairment charge in Q3 2026". source
Our view: The result is stated plainly: well-designed trial, no effect, and a higher proportion of people on ziltivekimab with serious infections. The announcement says ZEUS will not change the adjusted operating profit outlook but will bring a non-cash impairment charge in Q3 2026.
Legal and disclosure record · weight medium
IT-incident class actions and patent suits disclosed
The record says: Legal matters in the Q2 2026 report: "Novo Nordisk is a defendant in multiple putative class action lawsuits in the US related to an IT security incident about which the company issued a press release on 11 June 2026." It also lists a Sandoz suit filed on 30 June 2026 in the Unified Patent Court (Milan Central Division) seeking revocation of a semaglutide patent, and a false advertising suit Novo filed against Eli Lilly on 21 July 2026 in federal court in New Jersey. source
Our view: These are matters Novo discloses itself. The legal section does not list a securities class action, and the report does not quantify exposure from the IT-incident suits.
Stock chart
SEC filings and registration
- SEC name
- Novo Nordisk A S
- CIK
- 353278
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- NVO (NYSE), NONOF (OTC)
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- NOVO ALLE DK 2880, BAGSVAERD DENMARK, Denmark, 00000
- Phone
- 4544448888
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction